Cuestiones pendientes sobre los antipsicóticos clásicos y nuevos en la infancia y la adolescencia
Descargas
Publicado
Cómo citar
Número
Sección
Palabras clave:
Antipsicóticos, Infancia, AdolescenciaResumen
Cuarenta y cinco años de uso clínico de antipsicóticos clásicos (APC) han puesto de manifiesto tanto su eficacia en diversos trastornos de la infancia y la adolescencia como los riesgos de su uso abusivo e indulgente, o la presencia de reacciones adversas importantes (síntomas extrapiramidales, empeoramiento cognoscitivo). Los nuevos antipsicóticos bimodales (APB) parecen mantener la eficacia clínica, mejorar algunos otros aspectos sintomáticos que no cubrían los APC y dan lugar a menos reacciones adversas. Su utilización en psiquiatría de la infancia y la adolescencia deberá basarse en un conocimiento riguroso de sus propiedades y riesgos de utilización. Para ello son necesarios estudios que analicen la respuesta clínica, pero que también sean rigurosos en la medida de los síntomas extrapiramidales, las consecuencias cognitivas y otras reacciones adversas.
Descargas
Citas
Mardomingo Sanz MJ. Antipsicóticos, En: Psicofarmacología del niño y del adolescente. Madrid: Díaz de Santos; 1997; p. 61-99.
Castro Fornieles J. Agentes antipsicóticos o neurolépticos. En: Psicofarmacología clínica de la infancia y la adolescencia. Barcelona: Masson; 1998; p. 161-225.
Gutiérrez Casares JR, Martínez-Rey T, Fernández-Rivas A, Bolívar M. Psicofarmacología Infantil en Atención Primaria. II. Nuevos antipsicóticos. Atenc Prim Salud Mental 1998;1(3): 21-7.
Heuyer G, Gerard G, Galibert J. Traitement de l'excitation psychomotrice chez l'enfant. Arch Franchises Pediatr 1953¡9: 961.
Bair HU, Herold W. Efficacy of chlorpromazine in hyperactive mentally retarded children. Arch Neurol Psychiatry 1955;74:363. https://doi.org/10.1001/archneurpsyc.1955.02330160013003
Adamson WC. Chlorpromazine and Mental Health. Philadelphia: Lea and Feibiger; 1955.
Rettig JH. Chlorpromazine for the control of psychomotor excitement in mentally deficient: a preliminary study. J Nerv Mental Dis 1955;122:190-4. https://doi.org/10.1097/00005053-195508000-00008
Freedman AM, Effron A, Bender L. Pharmacotherapy in children with psychiatric illness. J Nerv Mental Dis 1955; 122: 479. https://doi.org/10.1097/00005053-195511000-00011
Heuyer G, Dell C, Pringuet G. F.mploi de chlorpromazine en neuro-psychiatrie infantile. Encéphale 1956;45:576.
Rogers WJB. Use of haloperidol in children's psychiatric disorders. Clin Trials J 1965;2:162-5.
Miksztal MW. Chlorpromazine and reserpine in residential treatment of neuropsychiatric disorders in children. J Nerv Mental Dis 1956;123:477-9. https://doi.org/10.1097/00005053-195605000-00009
Zimmermann RL, Heistad GT. Studies of the long term efficacy of Antipsychotic Drugs in controlling the behavior of Institutionalized Retardates. J Am Acad Child Adolesc Psychiatry 1982;21:136-43. https://doi.org/10.1016/S0002-7138(09)60912-2
Lipman RS. The use of psychopharmacological agents in residential facilities for the retarded. En: Menolascino FJ, ed. Psychiatric Approaches to Mental Retardation. New York: Basic Books; 1970. p. 387-98.
Sprage RL, Werry JS. Methodology of psychopharmacological studies with the retarded. En: Ellis RN, ed. International Review of Research in Mental Retardation. Vol 5. New York: Academic Press; p. 161-225.
Sprague RL. Principles of clinical trials and social, ethical and legal issues of drug use in children. En: Werry JS, ed. Pediatric Psychopharmacology. New York: Brunner-Mazel; 1978. p. 109-35.
Lipman RS, DiMascio A, Reating N, Kirson T. Drogas Psicotrópicas y Retardo Mental Infantil. En: Lipton, Dimascio, Killam, eds. Psicofarmacología. Barcelona: Espaxs; 1982.
DiMascio A, Soltys JJ, Shader RI. Psychotropic Drug Side Effects. En: DiMaschio, Shader, eds. Handbook of Psychopharmacology. New York: Science House; 1970.
Cantwell DP. Psychopharmacological Treatment of the Minimal Brain Dysfunction Syndrome. En: Wiener JM, ed. Psychopharmacology in Childhood and Adolescence. New York: Basic Books; 1977. p. 132.
Treatment of chidhood and adolescent schizophrenia. En: Wiener JM, ed. Psychopharmacology in Childhood and Adolescence. New York: Basic Books; 1977.
Shaw EB, Dermott RV, Lee R, Burbridge TN. Phenothiazine tranquillisers as a cause of severe seizures. Pediatrics 1959;23: 485.
Bush RT. Acute reactions to Prochroperazine in Children. A report of four cases. NZ Med J 1966;65:231-2.
Greenblatt DJ, Shader RI, DiMascio A. Extrapyramidal effects. En: Shader RL, DiMascio A, eds. Psychotropic Drug Side Effects. Baltimore: Williams & Wilkins; 1970. p. 92-106.
McAndrew J, Case Q, Treffert D. Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. J Autism Chid Schizophrenia 1972;2:75-91. https://doi.org/10.1007/BF01537628
Polizos P, Engelhardt D, Hoffman S, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophrenia 1973;3: 247-53. https://doi.org/10.1007/BF01538282
Paulson G, Rizvi A, Crane G. Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clin Ped 1975;14:953-5. https://doi.org/10.1177/000992287501401013
Engelhart D. Consequences of psychotropic drug withdrawal in autistic children: A follow-up report. Psychopharmacol Bull 1975;11:6-7.
Gualtieri CT, Barnhill J, McGimsey, Schell D. Tardive dyskinesia and other movement disorders in children treated with psychotropic drugs. J Am Acad Child Adolesc Psychiatry 1980;19:491-510. https://doi.org/10.1016/S0002-7138(09)61066-9
Fielding MT, Murphy RJ, Regan MW, Peterson TL. Drug and behavioral assessment to prevent excessive utilization of mayor tranquilizers with the mentally retarded. Hosp Commun Psychiatry 1980.
Taylor E. Drug Treatment. En: Rutter M, Hersow L, eds. Child and Adolescent Psychiatry. London: Blackwell Scienc Publications; 1985. p. 786.
Van Kammen DP, Marder SR. Antagonistas de los receptores de dopamina. En: Kaplan HI, BJ Sadock BJ, eds. Comprehensive Testbook of Psychiatry (1995). Ed. en castellano: Tratado de Psiquiatría. Buenos Aires: Inter-Médica; 1977. p. 1930-4.
Miller DD, O'Leary DS, Cizadlo T, Andreasen NC. Comparison of the effect of typical and atypical antipsychotics on regional cerebral blood flow in schizophrenia. XXIst CINP Congress, 1998. Abstract: PW15009.
Schulz E, Fleischhaker C, Clement HW, Remschmidt H. Boold biogenic amines during clozapine treatment of early- onset schizophrenia. J Neural Transm 1997;104:1077-89. https://doi.org/10.1007/BF01273320
Brosen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 1996;ll(Supl 1): 23-7. https://doi.org/10.1097/00004850-199603001-00005
Gefvert O, Bergstrom M, Langstróm B, et al. Time course of central nervous Dopamine-D2 and 5HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine in patients with schizophrenia. Psychopharmacol 1998;135:119-26. https://doi.org/10.1007/s002130050492
Richardson MA, Haugland G, Craig T. Neuroleptic use, parkinsonism-like symptoms, tardive diskinesia and associated factors in chil and adolescent psychiatric patients. Am J Psychiatry 1991;148:13228. https://doi.org/10.1176/ajp.148.10.1322
Grebb JA. Trastornos del movimiento inducidos por fármacos. En: Kaplan HI, Sadock BJ, eds. Tratado de Psiquiatría. 6 a ed. Edición en castellano: Buenos Aires: Intermédíca; 1997. p. 1827
Friedman JH. Drug-induced parkinsonism. En: Lang AF, Weiner WJ, eds. Drug-Induced Movement Disorders. New York: Futura; 1992. p. 49.
Armstrong M, Daly AK, Blennerhassett R, et al. Antipsychotic druginduced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997;170:23-6. https://doi.org/10.1192/bjp.170.1.23
Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute exprapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75. https://doi.org/10.4088/JCP.v59n0205
Kumra S, Jacobsen LK, Lelane M, et al. Case series: spectrum of neuroleptic-induced movement disorders and extra- pyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998;37:221-7. https://doi.org/10.1097/00004583-199802000-00016
American Psychiatric Association Task Force on Tardive Dyskinesia. Washington: Am Psych Ass.; 1992.
Castro Fornieles J. Op.cit. 1998; p. 177.
Nilsson A, Waller L, Rosengren A, et al. Cigarette smoking is associated with abnormal involuntary movements in the general male population-a study of men born 1933. Biol Psychiatry 1997;41:717-23. https://doi.org/10.1016/S0006-3223(96)00289-2
Casey DE. Extrapyramídal Syndromes, Epidemiology, Phatophysiology and the diagnostic Dilemma. CNS Drugs 1996:5(Supl 1):1-12. https://doi.org/10.2165/00023210-199600051-00003
Baldessarini RJ: Drugs and the treatment of psychiatric disorders. En: Goodman, Gilman's, eds. The Pharma- chological Basis of Therapeutics, New York: Pergamon Press; 1990. p. 383-435.
Ison MG. The effect of Thorazine on Wechsler scores. Am J Mental Def 1957;14:543-51.
Herper M, Willcott R, Garfield S. Effects of chorpromazine on learning and related processes in emotionaly disturbed children. J Cons Psychol 1963;27:1-9. https://doi.org/10.1037/h0044323
Sprage R, Barnes K, Werry J. Methylphenidate and thioridazine: learning, reacction time, activity and classroom behavioor in disturbed children. Am J Orthopsychiatry 1970; 40:615-28. https://doi.org/10.1111/j.1939-0025.1970.tb00719.x
Breuning S, Ferguson D, Davidson N, Poling A. Effects of thiotidazine on the intellectual performance of mentally retarded drug responders and nonresponders. Arch Gen Psychiatry 1983;40:309-13. https://doi.org/10.1001/archpsyc.1983.01790030079010
McAndrew JB, Case Q, Treffert DA. Effects of prolonged phenotiazine intake on psychotic and other hospitalized children. J Autism Childhood Schizophrenia 1972;2:75-91. https://doi.org/10.1007/BF01537628
Aman MG. Drugs, learning and the psychotherapies. En: Werry JS, ed. Pediatric Psychopharmacology. New York: Brunner-Mazel; 1978. p. 79-108.
Werry J, Aman M. Methilphenidate and haloperidol in children. Effects on attention, memory and activity. Arch Gen Psychiatry 1975;32:790-5. https://doi.org/10.1001/archpsyc.1975.01760240118009
Wong G, Cock R. Long-term effectsnof haloperidol on severely emotionally disturbed children. Aust NZ J Psychiatry 1971;5:296-300. https://doi.org/10.3109/00048677109159663
Cunningham M, Pillai V, Blachford-Rogers W. Haloperidol in the treatment of children with severe behaviour disorders. Br J Psychiatry 1968;114:845-54. https://doi.org/10.1192/bjp.114.512.845
Anderson LT, Campbell M, Grega DM, et al. Haloperidol in infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 1984;141:1195-201. https://doi.org/10.1176/ajp.141.10.1195
Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989;98(4):367-80. https://doi.org/10.1037/0021-843X.98.4.367
Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treated- refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12. https://doi.org/10.1016/0006-3223(93)90043-D
Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36: 71725. https://doi.org/10.1016/0006-3223(94)90082-5
Green MF, Marshall BD, Wirshing WC, et al. Does risperidone improve verbal working memory in treatmentresistant schizophrenia? Am J Psychiatry 1997;154:799-804. https://doi.org/10.1176/ajp.154.6.799
Gallhofer B, Bauer U, Gruppe H, et al. First episode schizophrenia: the importance of compliance and preserving cognitive function. J Pract Psychiatry Behav Health 1996; 2:16S-24S.
Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can T Psychiatry 1996:41(2 Supl):35S-40S. https://doi.org/10.1177/070674379604100823
Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study. Acta Psych Scand 1997;95:40-3. https://doi.org/10.1111/j.1600-0447.1997.tb00371.x
McGurk SR, Meltzer HY. The effects of atypical antipsychotic drugs on cognitie functioning in schizophrenia. XXIst CINP Congress. 1998; Abstract: PT07100. https://doi.org/10.1016/S0920-9964(97)88712-9
Canadian Cognition and Outcome Study Group. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone and haloperidol. Schizophren Res 1988;29:152-3. https://doi.org/10.1016/S0920-9964(97)88689-6
Gutierrez Casares JR (coordinador). Antipsicóticos en el Tratamiento de la Patología Psiquiátrica Infanto-Juvenil, VIII Congreso de la A Esp Psiq Infanto-Juvenil. Barcelona; 1998. p. 17-8.
Allison DB, Mentore JL, Heo M, et al. Weight gain associated with conventional and newer antipsychotics: A meta-analisys. XXIst CINP Congress, 1998; Abstract: PT07111. https://doi.org/10.1016/S0924-9338(99)80606-3
Kinon BJ, Basson B, Szymanski K, Tollefson GD. Factors associated with weight gain during olanzapine treatment, XXIst CINP Congress. 1998; Abstract: PT07053. https://doi.org/10.1016/S0924-977X(98)80361-1
Conley RR, Brecher MD. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Poster del XI Congress ECNP; 1998. https://doi.org/10.1016/S0924-977X(98)80413-6
Kumra S, Frazier J, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-7. https://doi.org/10.1001/archpsyc.1996.01830120020005
De Smedt G, Van Bellinger M. The effect of risperidone on behavioral disturbances in mentally retarded children and adolescents. XXIst CINP Congress, 1998. Abstract: PT 07020.
Kumra S, Herion D, Jacobsen LK, et al. Case study: risperidone-induced hepatotoxicity in pediatric patients J Am Acad Child Adolesc Psychiatry 1997;36:701-5. https://doi.org/10.1097/00004583-199705000-00022
© 2021 AEPNyA Todos los derechos reservados
